Tranche Update on Chong Kun Dang Holdings Corp.'s Equity Buyback Plan announced on August 12, 2022.

CHONGKUNDANG HOLDINGS CORP., formerly Chong Kun Dang Pharmaceutical Corp., is a Korea-based company engaged in the investment business. Through its subsidiary, the Company provides pharmaceuticals, including remedies for high blood pressure and high cholesterol, immunosuppressive drugs, antitumor agents, antibiotics, remedies for erectile dysfunction and remedies for obesity. It also produces antitumor agents, antibiotics, digestives, circulation agents, respiratory agents, remedies for endocrine diseases, remedies for skin diseases, functional cosmetics and others, as well as pharmaceutical ingredients. On November 2, 2013, the Company divested its pharmaceutical business into a newly established wholly owned subsidiary. After the divestiture, the Company engages in the investment and holding business.